<DOC>
	<DOCNO>NCT02628613</DOCNO>
	<brief_summary>The purpose study compare efficiency safety paclitaxel combine carboplatin vinorelbine combine epirubicin use neoadjuvant chemotherapy locally advanced ( IIb-IIIc ) HER-2 ( - ) breast cancer TEKT4 variation .</brief_summary>
	<brief_title>Neoadjuvant Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Epirubicin TEKT4 Variation Breast Cancer Patients</brief_title>
	<detailed_description>Taxane-based chemotherapy cornerstone treat breast cancer , however remarkable percentage breast cancer patient present primary secondary taxane resistance . Currently establish biomarker report clinically predict taxane sensitivity . Our previous study indicate TEKT4 variation decrease stability intracellular microtubule , TEKT4 variant cell behave high resistance microtubule-stabilizing agent taxane , enhance sensibility microtubule depolymerization agent vinorelbine . This study intend confirm TEKT4 variation predict prognosis taxane-based chemotherapy prospective clinical trial . This study intend evaluate efficiency safety two neoadjuvant therapy : paclitaxel combine carboplatin vinorelbine combine epirubicin , treat locally advance ( IIb-IIIc ) HER-2 ( - ) breast cancer TEKT4 variation . Primary endpoint study : pathologic Complete Response ( pCR ) . Secondary endpoint study : Relapse-free survival ( RFS ) , Disease-free survival ( DFS ) , Objective response rate ( CR+PR ) , Miller-Payne base response rate safety . Exploratory endpoint : Based biopsy sample baseline half treatment duration , correlation biomarker efficiency explore . This open single center prospective randomize control study include patient locally advanced ( IIb-IIIc ) HER-2 ( - ) patient TEKT4 variation diagnose histopathology Sanger sequencing . Patients randomize Group A Group B receive respective neoadjuvant chemotherapy . Among Group A : PC x 4 cycle ( paclitaxel + carboplatin ) , paclitaxel : 80 mg/m2 IV day 1 , 8 15 ; carboplatin : area curve ( AUC ) = 2 IV , day 1 8 , dose interval 21 day . Group B NE x 4 cycle ( vinorelbine + epirubicin ) , vinorelbine : 25 mg/m2 IV day 1 8 ; epirubicin : 60 mg/m2 IV day 1 , dose interval 21 day . Patients group perform diagnostic puncture treatment half treatment course order obtain information dynamic change Ki67 parameter ; Surgery perform 4 cycle chemotherapy , follow subsequent adjuvant therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Age : 1870 year old 2 . Expected survival &gt; 12 month 3 . Baseline ECOG Performance Status rating 01 4 . Naïve chemotherapy hormonal treatment 5 . Radiologically confirm biopsy diagnose invasive ductal carcinoma breast prepare treat surgically 6 . Locally advance breast cancer stage IIbIIIc 7 . HER2 negative confirm immunohistochemistry , Ki67≥20 % 8 . TEKT4 variation confirm DNA sequence 9 . No concurrent malignancy ( except control cervical carcinoma situ basal cell carcinoma skin ) 10 . Patients measurable lesion ( accord RECIST v1.1 criterion ) 11 . Intention cooperate baseline puncture neoadjuvant therapy 12 . No advanced metastasis metastasis involve brain liver 13 . Adequate bone marrow function , blood routine examination show neutrophil count ≥ 1.5x109/L , hemoglobin level ≥ 100 g/L , Platelets ≥ 100 x 109/L 14 . Adequate liver kidney function , serum aminotransferase ( AST ) ≤ 60U/L , serum total bilirubin ≤ 2.5 time ULN , serum creatinine ≤110μmol/L , urea nitrogen ≤7.1mmol/L 15 . No coagulation abnormality 16 . Normal heart function , normal ECG LVEF ≥ 55 % 17 . Women childbearing age agree take reliable contraceptive measure clinical trial , negative serum urine pregnancy test within 7 day prior administration 18 . No coagulation abnormality 19 . Sign inform consent statement voluntarily receive followup , treatment , laboratory test research procedures accord protocol . 1 . Previous regional systemic treatment breast cancer ( include limit chemotherapy , radiotherapy , target therapy , clinical trial ) 2 . Inflammatory breast cancer , bilateral breast cancer breast cancer already distant metastasis 3 . Complicated uncontrolled lung disease , severe infection , active peptic ulcer , blood clotting disorder , severe uncontrolled diabetes , connective tissue disorder bone marrow suppression , intolerance neoadjuvant therapy relate treatment 4 . Peripheral neuropathy &gt; 1 degree cause reason 5 . History congestive heart failure , uncontrolled symptomatic angina , arrhythmias history myocardial infarction , refractory hypertension ( systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 100 mmHg ) ; 6 . Breast cancer lactation pregnancy 7 . Unwillingly receive baseline puncture neoadjuvant therapy 8 . Mental illness incompliance treatment cause reason 9 . Known history severe hypersusceptibility agent use treatment protocol 10 . Patients receive major surgery suffer severe trauma within 2 month first administration 11 . Currently enroll recently use ( 30 day within enrollment ) agent research involve trial 12 . Known infected human immunodeficiency virus ( HIV ) 13 . Other circumstance consider inappropriate enrol researcher</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Neoadjuvant chemotherapy</keyword>
	<keyword>TEKT4</keyword>
</DOC>